Inspira Technologies Oxy B.H.N (Nasdaq:IINN) - Prezzo delle azioni, notizie e analisi

IINN Panoramica delle azioni

IINN analisi fondamentale
Punteggio fiocco di neve
Valutazione	1/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	4/6
Dividendi	0/6

Analisi del rischio

Realizza un fatturato inferiore a 1 milione di dollari ( $0 )

Gli utili sono diminuiti del 22.3% all'anno negli ultimi 5 anni

Gli azionisti sono stati sostanzialmente diluiti nell'ultimo anno

Gli ultimi report finanziari sono vecchi di più di 6 mesi

+ 1 più rischio

Inspira Technologies Oxy B.H.N. Ltd. Concorrenti

Neuronetics

NasdaqGM:STIM

US$29.4m

Vaso

OTCPK:VASO

US$22.7m

Femasys

NasdaqCM:FEMY

US$25.2m

IRIDEX

NasdaqCM:IRIX

US$29.4m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Inspira Technologies Oxy B.H.N
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$1.38
Massimo di 52 settimane	US$2.49
Minimo di 52 settimane	US$0.76
Beta	2.09
1Variazione di 1 mese	2.22%
Variazione a 3 mesi	23.21%
Variazione di 1 anno	35.29%
3Variazione a 3 anni	-54.15%
Variazione a 5 anni	n/a
Variazione dall'IPO	-70.95%

Notizie e aggiornamenti recenti

Recent updates

Inspira Technologies reports 1H results

Aug 11

Inspira stock soars 71% on developing non-invasive optical blood sensor Hyla

Jul 06

Rendimenti per gli azionisti

	IINN	US Medical Equipment	US Mercato
7D	7.8%	1.2%	2.0%
1Y	35.3%	22.6%	32.4%

Ritorno vs Industria: IINN ha superato il US Medical Equipment che ha restituito 22.6 % nell'ultimo anno.

Rendimento vs Mercato: IINN ha superato il mercato US che ha restituito 32.4 % nell'ultimo anno.

Volatilità dei prezzi

Is IINN's price volatile compared to industry and market?
IINN volatility
IINN Average Weekly Movement	6.5%
Medical Equipment Industry Average Movement	8.0%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: IINN non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale di IINN è diminuita da 12% a 6% nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2018	40	Dagi Ben-Noon	inspira-technologies.com

Inspira Technologies Oxy B.H.N. Ltd., società specializzata in dispositivi medici, è impegnata nella ricerca, nello sviluppo, nella produzione e nella commercializzazione di tecnologie proprietarie di supporto vitale per il trattamento dell'insufficienza respiratoria acuta. Il suo prodotto di punta è il dispositivo INSPIRA augmented respiration technology (Gen 2), un supporto vitale progettato per fornire un'ossigenazione adattiva del sangue che aumenta e stabilizza i livelli di saturazione dell'ossigeno in calo.

Inspira Technologies Oxy B.H.N. Ltd. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Inspira Technologies Oxy B.H.N con la sua capitalizzazione di mercato?
IINN statistiche fondamentali
Capitalizzazione di mercato	US$25.16m
Guadagni(TTM)	-US$11.29m
Ricavi(TTM)	n/a

0.0x

Rapporto P/S

-2.3x

Rapporto P/E

IINN è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
IINN Conto economico (TTM)
Ricavi	US$0
Costo del fatturato	US$0
Profitto lordo	US$0
Altre spese	US$11.29m
Guadagni	-US$11.29m

Ultimi guadagni dichiarati

Dec 31, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-0.61
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	0%

Come si è comportato IINN nel lungo periodo?

Vedi performance storica e confronto

IINN Panoramica delle azioni

Analisi del rischio

Inspira Technologies Oxy B.H.N. Ltd. Concorrenti

NasdaqGM:STIM

US$29.4m

OTCPK:VASO

US$22.7m

NasdaqCM:FEMY

US$25.2m

NasdaqCM:IRIX

US$29.4m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Inspira Technologies Oxy B.H.N. Ltd., Annual General Meeting, Dec 30, 2024

New minor risk - Financial data availability

Inspira Technologies Oxy B.H.N. Ltd. Announces Development of New Disposable Kit with Built-In Performance Monitoring Mechanism

Inspira Secures Second U.S. Patent Approval for Orbiting Blood Oxygenation Delivery System

Independent Chairman of the Board notifies of intention to sell stock

Inspira Technologies OXY B.H.N. Ltd. Announces FDA Listing and Market Readiness of New Product

Recent updates

Inspira Technologies Oxy B.H.N. Ltd., Annual General Meeting, Dec 30, 2024

New minor risk - Financial data availability

Inspira Technologies Oxy B.H.N. Ltd. Announces Development of New Disposable Kit with Built-In Performance Monitoring Mechanism

Inspira Secures Second U.S. Patent Approval for Orbiting Blood Oxygenation Delivery System

Independent Chairman of the Board notifies of intention to sell stock

Inspira Technologies OXY B.H.N. Ltd. Announces FDA Listing and Market Readiness of New Product

Inspira Technologies OXY B.H.N. Introduces the INSPIRA Cardi-ART, Aiming to Provide Oxygen to the Brain During Cardiac Arrest

New major risk - Shareholder dilution

Inspira Technologies OXY B.H.N. Ltd. Receives Israeli Regulatory Approval for the INSPIRA ART100 System

Inspira™ Introduces Advanced Life Support Solutions to Key International Leaders at the Annual iECOs Conference in Israel

Inspira™ Introduces Advanced Life Support Solutions to Key International Leaders at the Annual iECOs Conference in Israel

Inspira™ Announces Start of Production of the Inspira™ Art100

Price target increased by 44% to US$13.00

Inspira™? and Ennocure In Vitro Study Results Show 100% Prevention of Bacterial Growth Causes Bloodstream Infections

Inspira™ Technologies Oxy B.H.N. Ltd. Announces Program to Pioneer the Applicable Use of the INSPIRA™ ART100 Device for an Artificial Womb

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Inspira Technologies OXY B.H.N. Ltd. Announces AMAR Regulatory Submission of the INSPIRA™ ART100, to Enter the Southeast Asia and South American Markets

Inspira Releases New Data Demonstrating Superiority of its Core Technology, Across Key Endpoints of HMSS Indicator

Inspira Technologies OXY B.H.N. Ltd. Introduces High-End Platform for Bio-Mimicking Blood parameters for Development and Testing of Core Technologies

Inspiratm Technologies OXY B.H.N. Ltd. Receives First Ever U.S. Patent Approval for an Orbiting Blood Oxygenation Delivery System

New minor risk - Share price stability

Inspira Technologies Oxy B.H.N. Ltd. Announces Plans to Launch and Target Single-Use Disposable Blood Oxygenation Kit for A New Disposable Perfusion Market Opportunity

Inspira Technologies Oxy B.H.N. Ltd. has completed a Follow-on Equity Offering in the amount of $3.88 million.

Inspira Technologies Oxy B.H.N. Ltd. has filed a Follow-on Equity Offering in the amount of $3.88 million.

Inspira Technologies Oxy B.H.N. Ltd. has filed a Follow-on Equity Offering in the amount of $3.88 million.

Inspira Technologies OXY BHN Ltd. Announces 95% Accuracy Results for HYLA™? Blood Sensor, Planning FDA Submission for Clearance in 2024

Inspira Technologies Oxy B.H.N. Ltd. Announces Appointment of Dan Gorfil to its Medical Advisory Board

Inspira Technologies Oxy B.H.N. Ltd., Annual General Meeting, Dec 27, 2023

Inspira Technologies Oxy B.H.N. Ltd. Announces Israeli Innovation Authority Grant for New VORTX Disposable Blood Oxygenation Technology

Inspira Technologies OXY BHN Ltd. Announces the Grant of an Additional Patent by the U.S. Patent and Trademark Office for its Respiratory Medical Device, the INSPIRAART500

Inspira Technologies Unveils the Inspira™ Art Line of Medical Devices At the World's Largest Extracorporeal Life Support Conference

Inspira™? Announces 510(k) FDA Submission of INSPIRA™? ART100 Towards Commercialization

Inspira Technologies Appoints Dr. Nir as Chief Medical Officer

Inspira Technologies Oxy B.H.N. Ltd. to Reveal the New ALICE Device at the World's Largest Extracorporeal Life Support Conference

Inspira™ Technologies OXY B.H.N. Ltd. Develops the VORTX™ Blood Oxygenator, a Unique Technology for Saturating Blood With Oxygen and Removing Carbon Dioxide

Inspira(TM) Technologies Receives Approval from Sheba Medical Center to Conduct Clinical Study of the HYLA(TM) Blood Sensor

Inspira Technologies Receives Patent by U.S. Patent Office for the INSPIRA ART System's Convertible Dual Lumen Cannula Device and Method of Use

Inspira Technologies Oxy B.H.N. Ltd. Begins Manufacturing of the ALICE™ CPB Device, ahead of planned 2023 FDA submission

Less than half of directors are independent

Inspira Technologies Oxy B.H.N. Ltd. Receives Patent by the Israeli Patent Office for Key Safety Component for the INSPIRATM ART System

Chairman of the Board notifies of intention to sell stock

Inspira Technologies Oxy B.H.N. Ltd., Annual General Meeting, Oct 18, 2022

Inspira™ Technologies Performed HYLA™ Blood Sensor In-Vivo Study, in Preparation of Planned Human Studies

Inspira Technologies Oxy B.H.N. Ltd. Announces Changes in Management

Inspira Technologies reports 1H results

Inspira™ Technologies Reveals Next Generation Liby™ ECMO

Inspira Technologies Develops A Non-Invasive Blood Sensor

Inspira stock soars 71% on developing non-invasive optical blood sensor Hyla

Chairman of the Board notifies of intention to sell stock

Less than half of directors are independent

Inspira Technologies Appoints Daniella Yeheskely-Hayon as the New Chief Technology Officer

Inspira Technologies Oxy B.H.N. Ltd. Lists a Component of its ART and ECLS Systems on the U.S. Food and Drug Administration Class I 510(K) Exempt List

Inspira Technologies Oxy B.H.N. Ltd. Files A Pct Patent Application for Its Flagship Art Device and Proprietary Method of Use to Minimize the Need for Mechanical Ventilation

Inspira Technologies Oxy B.H.N. Ltd. has completed an IPO in the amount of $16.029091 million.

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda

Inspira Technologies Oxy B.H.N. Ltd. Riepilogo dei fondamenti

0.0x